-+ 0.00%
-+ 0.00%
-+ 0.00%

CytomX Therapeutics appoints Charles Fuchs to board of directors

PUBT·07/27/2026 12:02:44
Listen to the news
CytomX Therapeutics appoints Charles Fuchs to board of directors
  • CytomX Therapeutics appointed Charles Fuchs to its board of directors.
  • Fuchs most recently served as chief medical officer at Tubulis, overseeing clinical strategy and pipeline development.
  • He previously led oncology and hematology drug development at Genentech and Roche, advancing multiple therapies through approval.
  • CytomX flagged Fuchs’ gastrointestinal oncology experience as relevant to Varseta-M, its EpCAM-targeted ADC in development for metastatic colorectal cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270800PRIMZONEFULLFEED9765914) on July 27, 2026, and is solely responsible for the information contained therein.